Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY to make an "Oral Presentation" on Bracelet-1 at ASCO

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Apr 26, 2023 7:35pm

124 Views

Post# 35415909

RE:RE:RE:RE:RE:RE:RE:RE:ONCY to make an "Oral Presentation" on Bracelet-1 at ASCO

Noteable,

It is very helpful that you found the hypothesis for the study. Let us hope they stuck with the hypothesis and the results tell us something good about it. As you say, they are unlikely to be giving poor results in this event.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec